The link we observed between polymorphisms in HDAC3 and CTLA4 expression is supported by the study in which HDAC inhibitor Belinostat was found to potentiate the antitumor effect of anti-CTLA4 antibody in subcutaneous murine model of HCC [51]. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.